TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02836509
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 800 mg Ibuprofen in 150 ml normal saline given as a slow intravenous infusion over 5 minutes
Study: NCT03593473
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six intranasal sprays of placebo manufactured to mimic oxytocin nasal spray containing all equivalent ingredients except oxytocin.
Study: NCT02489916
Drug: CM4307
Approvals — FDA: no, EMA: no, PMDA: no
Description: CM4307 300mg bid, each 4 week cycle
Study: NCT02384317
Drug: CCX168
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCX168 30 mg, twice daily (b.i.d.) orally for 84 days (12 weeks). The CCX168 dose was taken in the morning, optimally within one hour after breakfast, and in the evening, optimally within one hour after dinner.
Study: NCT00128323
Drug: Gentian violet 0.00165% solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04234204
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT02863718
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 420mg daily
Study: NCT00402779
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet by mouth daily
Study: NCT02624817
Drug: Sulfonylurea
Normalized name: Sulfonylurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: See Arm description.
Study: NCT00816023
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: solution for IV infusion over the duration of the surgical\>\> procedure
Study: NCT03667716
Drug: COM701
Approvals — FDA: no, EMA: no, PMDA: no
Description: COM701 monotherapy.
Study: NCT03667716
Drug: COM701 with Opdivo (Nivolumab).
Approvals — FDA: no, EMA: no, PMDA: no
Description: COM701 in combination with Opdivo (Nivolumab).
Study: NCT01955473
Drug: Sym004
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part-A (dose-escalation): Sym004 will be administered intravenously either weekly at 6 to 12 milligram per kilogram (mg/kg) or biweekly at 18 mg/kg from Week 1 until unacceptable toxicity, disease progression, or consent withdrawal. Part-B (dose-expansion): After the maximum tolerated dose (MTD) is determined in Part-A, up to 30 additional subjects will continue to receive treatment in Part-B.
Study: NCT01433250
Drug: AIN457
Approvals — FDA: no, EMA: no, PMDA: no
Description: (10mg/kg i.v.).
Study: NCT04083625
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: a 10 cm syringe normal saline IV given just before skin incision of myomectomy.
Study: NCT04160546
Drug: Acetylsalicylic acid 100 MG
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive acetylsalicylic acid 100 mg/day for 104 weeks orally.
Study: NCT04262024
Drug: cabergoline 1.5-2 mg/week).orally daily for 1 month plus health education
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women with hyperprolactiemia scheduled for cabergoline therapy 1.5-2 mg/week). for one month will be offered health education to help minimize prolactin level(group A)
Study: NCT03543072
Drug: Bisphosphonates
Normalized name: Bisphosphonates
Approvals — FDA: no, EMA: no, PMDA: no
Description: a class of drugs that prevent the loss of bone density, used to treat osteoporosis and similar diseases
Study: NCT02265640
Drug: BIIL 284 BS boli
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02265640
Drug: BIIL 284 BS tablet C
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00709579
Drug: RV3391A
Approvals — FDA: no, EMA: no, PMDA: no
Description: A standardized quantity of each product will be applied on the evening on anterior side of forearm. The side of application will be randomized.
Study: NCT00709579
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT03233880
Drug: Azithromycin 1gm
Normalized name: AZITHROMYCIN 1GM/PKT PWDR,ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromicin 1 gm oral single dose
Study: NCT00093665
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00607906
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will also receive placebo capsules.
Study: NCT01892384
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT00590785
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose doxorubicin + cyclophosphamide (AC) x 6 cycles with G-CSF on Days 3 - 12 and followed in postmenopausal patients and hormone receptor-positive premenopausal patients by tamoxifen 20 mg daily for 5 years.
Study: NCT00590785
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: High-dose doxorubicin + cyclophosphamide (AC) x 6 cycles with G-CSF on Days 3 - 12 and followed in postmenopausal patients and hormone receptor-positive premenopausal patients by tamoxifen 20 mg daily for 5 years.
Study: NCT00003001
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003001
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02864953
Drug: BIIB093
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT02864953
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT03829878
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for CP101
Study: NCT03741478
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules visually identical to those containing olanzapine will be administered according to the same dosing schedule for each arm.
Study: NCT04089150
Drug: mFOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Day 1: oxaliplatin 85mg/m2 + irinotecan 150mg/m2 + leucovorin 50mg~* 5-FU 2400mg/m2 continuous IV infusion, 46 hour continuous infusion~* 14-day cycle, 6 cycles
Study: NCT04089150
Drug: Gemcitabine + Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: * Week 1, 2 and 3, qw: 1000 mg/m2 gemcitabine~* 21 days continuous: 830 mg/m2 oral capecitabine + 7 days rest~* 28-day cycle, 3 cycles
Study: NCT00515424
Drug: RKI983
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03381833
Drug: LJPC-401
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection, up to 20 mg per week from week 26 to 52
Study: NCT03381833
Drug: LJPC-401
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection, up to 20 mg per week from week 1 to 52
Study: NCT02487407
Drug: Placebo for ODM-109
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule for oral administration.
Study: NCT02398994
Drug: Intravenous Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02328404
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo film-coated tablet of Biodal 50,000 IU
Study: NCT01311635
Drug: AZD1981, current small-particle tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3x100 mg per oral, single dose in fasted state
Study: NCT02292732
Drug: ORTHO-NOVUM® tablet 1/35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each peach tablet will contain 1 mg of NE and 0.035 mg of EE. Other inactive ingredients will include lactose, magnesium stearate and pregelatinized corn starch
Study: NCT02292732
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each green tablet will contain only inert ingredients: D\&C yellow No. 10 Aluminum Lake, FD\&C Blue No. 2 Aluminum Lake, lactose, magnesium stearate, microcrystalline cellulose, and pregelatinized cornstarch. The tablets are to be taken orally and once daily
Study: NCT01311635
Drug: AZD1981, new small-particle tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3x100 mg per oral, single dose
Study: NCT01311635
Drug: AZD1981, new large-particle table
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3x100 mg per oral, single dose in fasted state
Study: NCT04233879
Drug: DOR/ISL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg DOR/0.75 mg ISL FDC tablet taken once daily by mouth.
Study: NCT04233879
Drug: BIC/FTC/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIC/FTC/TAF 50/200/25 mg FDC tablet taken once daily by mouth.
Study: NCT04233879
Drug: Placebo to BIC/FTC/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet matched to BIC/FTC/TAF taken by mouth.
Study: NCT04233879
Drug: Placebo to DOR/ISL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet matched to DOR/ISL taken by mouth.
Study: NCT04153136
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral tablet By mouth twice daily
Study: NCT00296608
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00296608
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02238470
Drug: oral anticoagulants
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of patients receiving oral anticoagulants with or without microbleeds in magnetic resonance imaging
Study: NCT03145558
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard of care for TACE
Study: NCT01910077
Drug: Tacrobell capsule 1mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule, oral, over the period I\&II(crossover)
Study: NCT03413176
Drug: Cardiac complication induced by VEGF/VEGFR inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Case reported in the World Health Organization (WHO) of cardiac complication of patient treated by AAs, with a chronology compatible with the drug toxicity
Study: NCT03177629
Drug: treatment : H. pylori eradication
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment: H. pylori eradication (pantoprazole, amoxicillin, clarithromycin, metronidazole) to treatment group at visit 1 and to control group 2nd stage at visit 4.~Day 1-5: pantoprazole 40mg bid, amoxicillin 1000mg bid, PO Day 6 - 10: pantoprazole 40mg bid, clarithromycin 500mg bid, metronidazole 500mg tid, PO
Study: NCT02758405
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 0.125% Bupivacaine plus fentanyl 2mcg/ml
Study: NCT01470989
Drug: ACZ885
Approvals — FDA: no, EMA: no, PMDA: no
Description: canakinumab 150 mg s.c., given on demand upon new flares
Study: NCT02940002
Drug: BAY1003803
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous application of 10μl on psoriasis plaque and on healthy skin for 4 weeks and evaluation of pharmacodynamic effect
Study: NCT03033147
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo 30 minutes before root canal treatment
Study: NCT00540618
Drug: MEDI-507
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compare in a placebo controlled manner, the disease activity of three dosing regimens of MEDI-507 (Monoclonal Antibody)
Study: NCT00540618
Drug: MEDI-507
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal Antibody (5 mg for 12 weeks and 5 mg for 6 weeks)
Study: NCT00540618
Drug: MEDI-507
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered 7 mg for 4 weeks by injection (Monoclonal Antibody)
Study: NCT03526861
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo contains the same excipients in the same concentration only lacking tralokinumab.
Study: NCT00853970
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: sterile ophthalmic solution
Study: NCT02205554
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nine doses administered every 6 hours.
Study: NCT00391118
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02591017
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02392559
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose of subcutaneous placebo treatment every 4 weeks
Study: NCT04770194
Drug: SP-8008 Prototype Capsule A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT04770194
Drug: SP-8008 Prototype Capsule B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT04770194
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT03467373
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 750 mg/m\^2 administered IV on Day 1 of each 21-day cycle
Study: NCT00842907
Drug: oral isotretinoin
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: one 20.0 mg capsule, once a day, every other day, during 24 weeks
Study: NCT03467373
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin 50 mg/m\^2 administered IV on Day 1 of each 21-day cycle
Study: NCT00842907
Drug: Tretinoin
Normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.05% tretinoin cream applied on face and forearms, once a day, in the night, during 24 weeks
Study: NCT00682097
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral doses
Study: NCT04330677
Drug: Placebo nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo spray contains the identical ingredients, except for the peptide itself. It will be given 30 minutes before the fear extinction task (Study 1) or fMRI measurement (Study 2).
Study: NCT04330677
Drug: Placebo Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received a single dose of the placebo gel (ultrasonic gel, 2 mg), applied to their shoulder, 3 hours prior to the fear extinction task (Study 1) or fMRI measurement (Study 2).
Study: NCT00535288
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encapsulated placebo tablets in Swedish Orange hard gelatin DB-B capsules for blinding purposes. Encapsulated tablets were administered orally once daily in the evening prior to sleep for 12 weeks.
Study: NCT01007630
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5mg for 14 days, then switch to 1mg for remainder of the study (approximately 10 weeks total)
Study: NCT04615455
Drug: Cryostor CS10
Normalized name: CRYOSTOR CS5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CryoStor® CS10 freeze medium
Study: NCT00745849
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00970775
Drug: AZD2423
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral solution, single dose
Study: NCT00970775
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral solution,single dose
Study: NCT04013243
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline 50ml infusion for loading dose followed by continuous infusion for same dose of magnesium.
Study: NCT03188172
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy
Study: NCT04180384
Drug: Oraxol
Normalized name: doxycycline hyclate Oral Capsule [Oraxyl]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel:~5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13- ester with (2R,3S)-N-benzoyl-3-phenylisoserine~HM30181 methanesulfonate monohydrate:~N-(2-(2-(4-(2-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl)-4-oxo-4H-chromene-2-carboxamide Methanesulfonate monohydrate
Study: NCT00576680
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally once a day
Study: NCT02661178
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01126359
Drug: Placebo-Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control dressing change: iv or po pain medication and injection of 0.9% normal saline retrograde up the suction tube.
Study: NCT01010139
Drug: Codeine Sulfate
Normalized name: Codeine Sulfate
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15 mg, 30 mg and 60 mg Tablet
Study: NCT02177487
Drug: Telmisartan/hydrochlorothiazide
Normalized name: telmisartan/hydrochlorothiazide 80 mg-25 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01916759
Drug: Seasonal trivalent inactivated influenza vaccine (Vaxigrip®)
Normalized name: diphtheria toxoid vaccine, inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administer seasonal trivalent inactivated influenza vaccine (Vaxigrip®) and collect blood specimens at 0, 1, 3, 7, 14, 28 and 100 days following vaccination.
Study: NCT02632903
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00301873
Drug: IV Zometa
Normalized name: zoledronic acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zometa will be given at 4 mg intravenously over 15 minutes every 3 months for 1 year.
Study: NCT02662556
Drug: sufentanil sublingual tablet 30 mcg
Normalized name: sufentanil Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: sufentanil sublingual tablet 30 mcg as needed for pain management, but no more frequently than every 60 minutes, for up to 12 hours.
Study: NCT02242331
Drug: Micardis®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03970252
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03970252
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03014882
Drug: L-Carnitine and N-acetyl cysteine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00775203
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02679963
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01203644
Drug: SKY0402
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of SKY0402 administered locally into the surgical wound.
Study: NCT01732666
Drug: low dose remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml of 0.9% saline immediately after anesthesia induction and 0.05µg/kg/min of remifentanil during anesthesia.
Study: NCT04049448
Drug: ABX464
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects will receive ABX464 administered at 50 mg o.d for an overall period of 2 years (104 weeks).
Study: NCT01860729
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03724851
Drug: TEW-7197
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vactosertib will be administered orally without regard to meals for 5 days per week (5D/W) at the same time in the morning (QD), at the same time in the morning and evening (BID) approximately 12 hours apart.~Pembrolizumab will be administered as a dose of 200 mg using a 30-minute IV infusion. Sites should make every effort to target infusion timing to be as close to 30 minutes as possible.
Study: NCT02724579
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01609127
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1250 mg/m2 orally twice daily (in the morning and evening after a meal; equivalent to a total daily dose of 2500 mg/m2) on Day 1 through Day 14 of each 21-day cycle
Study: NCT00864916
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo three times per day for 48 weeks.
Study: NCT00992589
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules once daily in the morning.
Study: NCT02827656
Drug: hCG luteal support
Approvals — FDA: no, EMA: no, PMDA: no
Description: luteal support as described and vaginal progesterone 200 mg 3 times a day
Study: NCT01849887
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03355482
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM saline injection at baseline
Study: NCT03996369
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etrasimod matching placebo tablet by mouth, once daily up to 12-Week Induction Treatment Period
Study: NCT00609063
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules taken daily for 6 months
Study: NCT01432600
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The dose escalation uses a standard 3x3 design: Ex: If none of the first 3 participants have a DLT, enter 3 participants at the next higher dose level. Once the maximum tolerated dose (MTD) of oral weekly cyclophosphamide in combination with pomalidomide and dexamethasone was determined, investigators proceeded with the second phase of the trial, a randomized phase II study comparing pomalidomide and dexamethasone with pomalidomide, dexamethasone and oral weekly cyclophosphamide delivered at the MTD determined in the phase I study.
Study: NCT03799094
Drug: Tyrosine kinase inhibitor
Normalized name: Protein-tyrosine kinase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive Tyrosine kinase inhibitor therapy in cycles: continuous treatment at the indicated dose.
Study: NCT01453582
Drug: Total Flavonoids of Propolis dropping pill
Normalized name: propolis Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: One pack contains 30 pills, weight 33g. One pack each time, three times a day, 14 days a course.
Study: NCT01453582
Drug: total Flavonoids of Propolis dropping pill
Normalized name: propolis Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: One pack contains 30 pills, weight 33g. One pack each time, three times a day, 14 days a course.
Study: NCT01150409
Drug: hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1) Hydrocortisone 50 mg IV every 12 hours x 4 doses (2 days), followed by Hydrocortisone 50 mg IV every 24 hours x 2 doses (2 days)